EU remote
Director, Market Access, Netherlands
About this role
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients. The Opportunity: The Market Access Director, Netherlands is responsible for defining and executing the country market access strategy to ensure timely, sustainable patient access to innovative oncology therapies. This role shapes reimbursement and access strategy, drives value demonstration, and leads engagement with key external stakeholders including payers, HTA bodies, and health authorities.
This position will partner with regulatory, commercial and medical affairs teams to deliver launch activities by providing access insights, developing evidence-based HTA, Pricing & Reimbursement dossiers and tools, engaging with market access and public affairs stakeholders as well as driving pricing strategy activities, and lead the activities to deliver access results supporting the overall success of the product launches aligned with patient needs.
Lead Market Access & Reimbursement: Develop and implement strategies to support access and pricing decisions for RevMed portfolio and launches within the Netherlands healthcare system. HTA & Pricing Filings: Lead preparation and submission of value dossiers, benefit assessments and pricing negotiations with statutory health insurance decision makers. Partner with regional and local Medical Affairs and Marketing team to translate clinical and economic evidence into compelling value communications tailored for Netherlands payers.